LB MED
ActiveFinancials · financial year 2025, micro format
Annual accounts 2025 filed on 08-06-2026 at the NBB all 2 filings
Every figure per financial year
The operating result for 2025 is a profit of €52,834, after a loss of €1,554 in 2024.
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Investments
| Item | 2024 | 2025 |
|---|---|---|
| Tangible fixed assets | - | €36,990 |
| Depreciation and write-downs of the year | - | €4,864 |
Source: notes to the 2024 to 2025 annual accounts (statement of fixed assets)
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | - | €4,864 | - |
| Other operating charges640/8 | - | €63 | - |
| Gross operating margin9900 | -€1,554 | €57,762 | - |
| Operating profit (loss)9901 | -€1,554 | €52,834 | - |
| Financial charges65/66B | - | €666 | - |
| Recurring financial charges65 | - | €666 | - |
| Profit (loss) for the period before taxes9903 | -€1,554 | €52,168 | - |
| Income taxes67/77 | - | €10,000 | - |
| Profit (loss) for the period9904 | -€1,554 | €42,168 | - |
| Profit (loss) for the period to be appropriated9905 | -€1,554 | €42,168 | - |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €3,000 | €93,829 | ▲ 31× |
| Fixed assets21/28 | - | €32,126 | - |
| Tangible fixed assets22/27 | - | €32,126 | - |
| Furniture and vehicles24 | - | €32,126 | - |
| Current assets29/58 | €3,000 | €61,703 | ▲ 21× |
| Cash at bank and in hand54/58 | €3,000 | €60,970 | ▲ 20× |
| Deferred charges and accrued income490/1 | - | €733 | - |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €3,000 | €93,829 | ▲ 31× |
| Equity10/15 | €1,446 | €43,614 | ▲ 30× |
| Contributions10/11 | €3,000 | €3,000 | = |
| Profit (loss) carried forward14 | -€1,554 | €40,614 | - |
| Amounts payable17/49 | €1,554 | €50,214 | ▲ 32× |
| Amounts payable after more than one year17 | - | €16,929 | - |
| Financial debts170/4 | - | €16,929 | - |
| Amounts payable within one year42/48 | €1,554 | €33,285 | ▲ 21× |
| Current portion of amounts payable after more than one year42 | - | €12,269 | - |
| Financial debts43 | - | €3,516 | - |
| Credit institutions430/8 | - | €3,516 | - |
| Trade debts44 | €1,554 | - | - |
| Suppliers440/4 | €1,554 | - | - |
| Taxes, remuneration and social security45 | - | €17,500 | - |
| Taxes450/3 | - | €10,000 | - |
| Remuneration and social security454/9 | - | €7,500 | - |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | -€1,554 | €42,168 | - |
| + Depreciation and write-downs630 | - | €4,864 | - |
| Operating cash flow (approximation) | -€1,554 | €47,033 | - |
| Change in cash | - | €57,970 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 11,279 companies had the same profile as LB MED has now. Two years later, 96.6% were still going and 0.7% had gone bankrupt.
- Micro
- under 2 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
That fits the bankruptcy probability of LB MED itself: 0.3% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 11,279 companies, not a prediction for LB MED. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.